Skip to main content
icon for Who will Trump announce as next FDA commissioner?
Politika·FDA

Who will Trump announce as next FDA commissioner?

icon for Who will Trump announce as next FDA commissioner?
Politika·FDA

Who will Trump announce as next FDA commissioner?

Kyle Diamantas 53%

No announcement by December 31 10.0%

Stephen Hahn 4%

Brett Giroir 3.7%

Polymarket
BAGO

Kyle Diamantas 53%

No announcement by December 31 10.0%

Stephen Hahn 4%

Brett Giroir 3.7%

Polymarket
BAGO

Kyle Diamantas

$1,525 Vol.

53%

Stephen Hahn

$976 Vol.

4%

Brett Giroir

$1,510 Vol.

4%

Grace Graham

$1,893 Vol.

3%

Sara Brenner

$849 Vol.

3%

No announcement by December 31

$533 Vol.

10%

This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Following Marty Makary's resignation as FDA commissioner earlier this month, President Trump appointed Kyle Diamantas as acting commissioner. Diamantas, previously the deputy overseeing the agency's food program with longstanding administration ties, now holds the interim role amid Senate confirmation requirements for any permanent successor. This immediate elevation has driven trader consensus toward Diamantas at 53% implied probability, reflecting the practical edge of acting status and White House endorsement in filling the vacancy. The 11.6% probability attached to no announcement by December 31 incorporates potential delays in the confirmation process, while lower odds for figures such as Stephen Hahn and Brett Giroir align with their comparatively limited recent visibility in administration health policy discussions.

This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.

An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.

Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.

Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.

A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.

If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.

The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Volume
$7,286
Petsa ng Pagtatapos
Dec 31, 2026
Binuksan ang Market
May 12, 2026, 7:59 PM ET

Resolver

0x69c47De9D...
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Following Marty Makary's resignation as FDA commissioner earlier this month, President Trump appointed Kyle Diamantas as acting commissioner. Diamantas, previously the deputy overseeing the agency's food program with longstanding administration ties, now holds the interim role amid Senate confirmation requirements for any permanent successor. This immediate elevation has driven trader consensus toward Diamantas at 53% implied probability, reflecting the practical edge of acting status and White House endorsement in filling the vacancy. The 11.6% probability attached to no announcement by December 31 incorporates potential delays in the confirmation process, while lower odds for figures such as Stephen Hahn and Brett Giroir align with their comparatively limited recent visibility in administration health policy discussions.

This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.

An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.

Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.

Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.

A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.

If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.

The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Volume
$7,286
Petsa ng Pagtatapos
Dec 31, 2026
Binuksan ang Market
May 12, 2026, 7:59 PM ET

Resolver

0x69c47De9D...
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.

Mag-ingat sa mga external link.

Mga Madalas na Tanong

Ang "Who will Trump announce as next FDA commissioner?" ay isang prediction market sa Polymarket na may 6 posibleng outcomes kung saan bumibili at nagbebenta ang mga trader ng shares batay sa kanilang pinaniniwalaan na mangyayari. Ang kasalukuyang nangunguna ay "Kyle Diamantas" sa 53%, sinusundan ng "No announcement by December 31" sa 10%. Ang mga presyo ay sumasalamin sa real-time crowd-sourced probabilities. Halimbawa, ang isang share na naka-presyo sa 53¢ ay nagpapahiwatig na kolektibong itinatakda ng market ang 53% na tsansa sa outcome na iyon. Patuloy na nagbabago ang mga odds na ito habang tumutugon ang mga trader sa mga bagong development at impormasyon. Ang mga shares sa tamang outcome ay mare-redeem sa $1 bawat isa sa market resolution.

Ang "Who will Trump announce as next FDA commissioner?" ay isang bagong likhang market sa Polymarket, inilunsad noong May 13, 2026. Bilang isang maagang market, ito ang iyong pagkakataon na maging kabilang sa mga unang trader na magtakda ng odds at mag-establish ng mga paunang price signal ng market. Maaari mo ring i-bookmark ang pahinang ito para subaybayan ang volume at trading activity habang lumalaki ang market sa paglipas ng panahon.

Para mag-trade sa "Who will Trump announce as next FDA commissioner?," i-browse ang 6 available na outcomes na nakalista sa pahinang ito. Ang bawat outcome ay may kasalukuyang presyo na kumakatawan sa implied probability ng market. Para kumuha ng posisyon, piliin ang outcome na pinaniniwalaan mong pinaka-malamang, piliin ang "Yes" para mag-trade pabor dito o "No" para mag-trade laban dito, ilagay ang iyong halaga, at i-click ang "Trade." Kung tama ang iyong napiling outcome kapag na-resolve ang market, nagbabayad ang iyong "Yes" shares ng $1 bawat isa. Kung mali, nagbabayad ang mga ito ng $0. Maaari ka ring magbenta ng iyong shares anumang oras bago ang resolution kung gusto mong i-lock in ang kita o bawasan ang pagkalugi.

Ang kasalukuyang frontrunner para sa "Who will Trump announce as next FDA commissioner?" ay "Kyle Diamantas" sa 53%, ibig sabihin itinatakda ng market ang 53% na tsansa sa outcome na iyon. Ang sumunod na pinaka-malapit na outcome ay "No announcement by December 31" sa 10%. Nag-a-update ang mga odds na ito sa real-time habang bumibili at nagbebenta ang mga trader ng shares, kaya sinasalamin nila ang pinakabagong kolektibong view kung ano ang pinaka-malamang na mangyari. Bumalik nang madalas o i-bookmark ang pahinang ito para sundan kung paano nagbabago ang odds habang lumilitaw ang bagong impormasyon.

Ang mga resolution rules para sa "Who will Trump announce as next FDA commissioner?" ay tiyak na nagde-define kung ano ang kailangang mangyari para sa bawat outcome na maideklara bilang panalo — kasama ang mga opisyal na data source na ginagamit para matukoy ang resulta. Maaari mong i-review ang kumpletong resolution criteria sa "Rules" section sa pahinang ito sa itaas ng mga komento. Inirerekomenda namin na basahin nang mabuti ang mga patakaran bago mag-trade, dahil tinutukoy nila ang mga tiyak na kondisyon, edge cases, at mga source na namamahala kung paano nise-settle ang market na ito.